跳至主要内容
临床试验/NCT01714427
NCT01714427已完成不适用

Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment

Medical University of Vienna1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2011年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
36
试验地点
1
主要终点
The effects of LPS instillation on a putative microvascular leak formation in a lung subsegment by radiologic imaging (magnetic resonance imaging, computed tomography) will be quantified.

研究概览

简要总结

The purpose of this study is to investigate the local and systemic inflammatory response and haemostatic alterations in the lungs after lipopolysaccharide (LPS) instillation and to determine the feasibility of imaging techniques to quantify lung inflammation in an adapted human endotoxin instillation model.

The investigators will also explore whether glucocorticoid treatment can blunt LPS effects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
19 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent obtained before any trial-related activities. (Trial activities are any procedure that would not have been performed during normal management of the subject).
  • Nonsmoker
  • Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
  • Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant
  • If female and of childbearing potential and subjects agrees to employ adequate birth control measures (e. g. oral contraceptives, barrier method)
  • Negative urine pregnancy test

排除标准

  • Known or suspected allergy to trial product or related products
  • Pregnancy or Lactation
  • Treatment with an investigational drug within three weeks prior to this trial
  • Participation in an LPS trial within the last 6 weeks
  • History of relevant cardiac arrhythmia
  • Preexisting open or closed angle glaucoma
  • History of Osteoporosis, Cushing´s syndrome, gastro-duodenal ulcera, cardiovascular disease, vasculitis, diabetes mellitus, hypertension, brain tumor or history of neurosurgery
  • Systemic tuberculosis
  • Hemorrhagic diathesis
  • Relevant liver or kidney dysfunction
  • Regular use of medication or abuse of alcohol unless considered clinically relevant
  • Use of any medication within one week prior to the first trial day
  • Symptoms of a clinically relevant illness in the 3 weeks before the first trial day
  • Excessive sporting activities
  • Subjects on Monoamine oxidase inhibitors (should be stopped for at least two to three weeks before dihydrocodeine treatment is initiate)
  • Known acute or active hepatic disease within the past 3 months
  • A platelet count < 100,000 x 106/L, prothrombin time > 1.5, liver enzymes> 3 times the upper normal limit
  • Having received a vaccination up to 8 weeks before the trial

研究组 & 干预措施

Dexamethasone

Active Comparator

干预措施: Dexamethasone (Drug)

Sterile isotonic saline

Placebo Comparator

干预措施: Sterile isotonic saline (Drug)

结局指标

主要结局

The effects of LPS instillation on a putative microvascular leak formation in a lung subsegment by radiologic imaging (magnetic resonance imaging, computed tomography) will be quantified.

时间窗: 6/24 hours after LPS Instillation

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Bernd Jilma

Associate Professor of Clinical Pharmacology & Internal Medicine

Medical University of Vienna

研究点 (1)

Loading locations...

相似试验